File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3390/ph3103186
- Scopus: eid_2-s2.0-78650103811
- WOS: WOS:000437570600007
Supplementary
- Citations:
- Appears in Collections:
Article: The biochemical basis of Hydroxymethylglutaryl-coa reductase inhibitors as neuroprotective agents in aneurysmal subarachnoid hemorrhage
Title | The biochemical basis of Hydroxymethylglutaryl-coa reductase inhibitors as neuroprotective agents in aneurysmal subarachnoid hemorrhage |
---|---|
Authors | |
Keywords | Aneurysm Hydroxymethylglutaryl-CoA reductase inhibitors Neuroprotective agent Subarachnoid hemorrhage |
Issue Date | 2010 |
Citation | Pharmaceuticals, 2010, v. 3, n. 10, p. 3186-3199 How to Cite? |
Abstract | Aneurysmal subarachnoid hemorrhage (SAH) has the highest morbidity and mortality rates of all types of stroke. Many aneurysmal SAH patients continue to suffer from significant neurological morbidity and mortality directly related to delayed cerebral ischemia. Pilot clinical studies of the use of Hydroxymethylglutaryl-CoA Reductase Inhibitors (statins) in aneurysmal SAH patients have reported a reduction in delayed cerebral ischemia and better clinical outcomes. We review the biochemical effects of statins on endothelium vascular function, glutamate-mediated neurotoxicity, inflammatory changes, and oxidative injuries, with reference to their possible neuroprotective effects in aneurysmal SAH. © 2010 by the authors. |
Persistent Identifier | http://hdl.handle.net/10722/325615 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wong, George Kwok Chu | - |
dc.contributor.author | Poon, Wai Sang | - |
dc.date.accessioned | 2023-02-27T07:34:46Z | - |
dc.date.available | 2023-02-27T07:34:46Z | - |
dc.date.issued | 2010 | - |
dc.identifier.citation | Pharmaceuticals, 2010, v. 3, n. 10, p. 3186-3199 | - |
dc.identifier.uri | http://hdl.handle.net/10722/325615 | - |
dc.description.abstract | Aneurysmal subarachnoid hemorrhage (SAH) has the highest morbidity and mortality rates of all types of stroke. Many aneurysmal SAH patients continue to suffer from significant neurological morbidity and mortality directly related to delayed cerebral ischemia. Pilot clinical studies of the use of Hydroxymethylglutaryl-CoA Reductase Inhibitors (statins) in aneurysmal SAH patients have reported a reduction in delayed cerebral ischemia and better clinical outcomes. We review the biochemical effects of statins on endothelium vascular function, glutamate-mediated neurotoxicity, inflammatory changes, and oxidative injuries, with reference to their possible neuroprotective effects in aneurysmal SAH. © 2010 by the authors. | - |
dc.language | eng | - |
dc.relation.ispartof | Pharmaceuticals | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Aneurysm | - |
dc.subject | Hydroxymethylglutaryl-CoA reductase inhibitors | - |
dc.subject | Neuroprotective agent | - |
dc.subject | Subarachnoid hemorrhage | - |
dc.title | The biochemical basis of Hydroxymethylglutaryl-coa reductase inhibitors as neuroprotective agents in aneurysmal subarachnoid hemorrhage | - |
dc.type | Article | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3390/ph3103186 | - |
dc.identifier.scopus | eid_2-s2.0-78650103811 | - |
dc.identifier.volume | 3 | - |
dc.identifier.issue | 10 | - |
dc.identifier.spage | 3186 | - |
dc.identifier.epage | 3199 | - |
dc.identifier.eissn | 1424-8247 | - |
dc.identifier.isi | WOS:000437570600007 | - |